Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997411 | 0.91 | MEN1 (0.34) | OPRD1SLC6A2SLC6A4CHRM5CHRM3 | |
| SCHEMBL10522315 | 0.91 | MEN1 (0.34) | OPRD1SLC6A2SLC6A4CHRM5CHRM3 | |
| SCHEMBL63693 | 0.78 | CXCR4 (0.35) | OPRM1OPRD1OPRK1SLC6A2SLC6A4 | |
| SCHEMBL2907938 | 0.78 | CXCR4 (0.35) | OPRM1OPRD1OPRK1SLC6A2SLC6A4 | |
| SCHEMBL109412 | 0.77 | FDPS (0.32) | — | |
| SCHEMBL24606523 | 0.76 | CXCR4 (0.39) | OPRM1OPRD1OPRK1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4430349 | 0.76 | CXCR4 (0.34) | OPRM1OPRD1OPRK1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1169999 | 0.76 | CXCR4 (0.34) | OPRM1OPRD1OPRK1SLC6A2SLC6A4 | |
| Piperazine SCHEMBL28274258 | 0.75 | MC4R (0.33) | OPRM1CHRM5CHRM3 | |
| SCHEMBL13509553 | 0.74 | CXCR4 (0.42) | OPRM1OPRD1OPRK1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | OPRM1 51/4885OPRD1 60/4885OPRK1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.